Can GLP-1 Drugs Like Zepbound Help With Symptoms?

• New analysis has discovered that GLP-1 medicine could enhance obstructive sleep apnea (OSA) associated to weight problems.
• The results of tirzepatide (Zepound), which is FDA permitted for OSA, had been particularly notable.
• GLP-1s seem to enhance OSA related to weight problems by selling fats loss within the neck, throat, and tongue.
• CPAP remedy needs to be continued till a doctor has confirmed remission with a sleep examine.

GLP-1 drugs prescribed for weight reduction, comparable to Zepbound and Wegovy, present promise for alleviating signs related to sleep apnea.

A brand new analysis overview printed in JAMA Otolaryngology on September 3 discovered that glucagon-like peptide-1 (GLP-1) receptor agonists could supply vital enchancment in obstructive sleep apnea (OSA) associated to weight problems.

The results had been very true for tirzepatide (Zepbound, Mounjaro), which additionally acts on glucose-dependent insulinotropic polypeptide (GIP) receptors. Zepbound is already permitted by the Meals and Drug Administration (FDA) to assist deal with sleep apnea.

The National Council on Aging explains that OSA happens when the muscle tissues and tissues throughout the throat loosen up throughout sleep, blocking the airway. Whereas CPAP machines are the usual therapy for this situation, weight reduction is usually really helpful as nicely since it will probably scale back fats within the neck and tongue, serving to to maintain the airway open.

The authors of the overview discovered that in one of many trials studied, weight reduction with tirzepatide lowered the variety of respiratory interruptions, as measured by the apnea-hypopnea index (AHI), by roughly 20–24 per hour, compared with placebo.

Moreover, as much as half of the individuals achieved full remission of their signs. The researchers did notice, nevertheless, that CPAP remained the superior therapy.

For this overview of research, the analysis crew examined a number of scientific databases, together with PubMed, Cochrane Library, ClinicalTrials.gov, and Google Scholar.

They regarded for research printed between 2016 and 2025 to see what had been discovered about GLP-1s and sleep apnea following an preliminary medical trial referred to as the SCALE Sleep Apnea trial.

The search included phrases associated to GLP-1 receptor agonists (comparable to tirzepatide, semaglutide, and liraglutide) and key sleep apnea outcomes, together with the apnea-hypopnea index (AHI), higher airway neuromuscular perform, and inflammatory pathways.

The authors included randomized medical trials, systematic critiques, meta-analyses, and observational research that reported polysomnographic outcomes or validated patient-reported sleep measures.

Research exploring how these medicine could have an effect on respiratory, muscle perform, and inflammation had been additionally reviewed to assist clarify the medical findings. Nonetheless, they didn’t embrace any case studies.

Knowledge had been then extracted to summarize examine designs, populations, interventions, outcomes, and mechanisms.

The objective was to synthesize the at present out there proof to information medical observe and search for potential areas for future analysis.

After reviewing the literature, the researchers discovered that the first mechanism by which GLP-1 receptor agonists enhance OSA is thru weight reduction, which reduces fats across the neck, tongue, and throat. This helps hold the airway open throughout sleep.

Analysis exhibits a transparent relationship between weight reduction and OSA enchancment: shedding 10% of body weight is linked to a 26% discount within the apnea-hypopnea index (AHI).

These medicine additionally seem to scale back tongue fats, an necessary contributor to airway blockage.

Past weight reduction, rising analysis means that GLP-1 receptor agonists could have an effect on the mind and nerves that management respiratory.

They could assist stabilize respiratory by altering the sensitivity of respiratory management methods, though extra human analysis is required.

GLP-1 therapies might also enhance leptin signaling, which may assist assist the muscle tissues that hold the higher airway open throughout sleep.

OSA additionally causes irritation and oxidative stress due to repeated drops in oxygen. GLP-1 receptor agonists have anti-inflammatory results and will assist shield airway muscle tissues from injury attributable to repeated oxygen drops. Nonetheless, a lot of this proof comes from animal research and wishes additional testing in people.

Scientific trials have additionally proven significant enhancements in OSA severity. Within the SURMOUNT-OSA section 3 trials, tirzepatide lowered AHI by 20 to 24 occasions per hour, with 42% to 50% of sufferers reaching illness remission.

Enhancements appeared as early as 4 weeks, earlier than most weight reduction was reached, suggesting the medicine could present advantages past weight discount.

Liraglutide additionally improved AHI and lowered weight within the SCALE Sleep Apnea trial.

The researchers say that though GLP-1 agonists don’t match CPAP’s effectiveness, they might be a helpful different or addition for individuals who can not tolerate CPAP or who must drop pounds earlier than surgical procedure.

Nonetheless, necessary questions stay about how lengthy the advantages final after therapy stops, whether or not the medicine assist individuals with out weight problems, and their long-term value and cardiovascular results.

Ruchir P. Patel, MD, FACP, a sleep medication specialist and vice chairman and senior medical director at Inspire Medical Systems, mentioned that GLP-1 drugs could supply a further therapy choice exterior of CPAP remedy. Patel wasn’t concerned within the overview.

Whereas CPAP could be very efficient, in accordance with Patel, long-term adherence to the therapy is troublesome to realize.

“Tirzepatide, nevertheless, addresses a single danger issue within the setting of OSA — weight problems,” he advised Healthline. “There are different components concerned within the growth of OSA, together with simply structural anatomy unrelated to fats deposits that can’t be addressed by weight reduction.”

Subsequently, whereas tirzepatide might help goal this danger issue, Patel emphasizes that the medical neighborhood, in addition to sufferers, shouldn’t take the view that we have now discovered a treatment.

“[W]e have recognized for a few years by means of the bariatric surgery literature that vital weight reduction doesn’t all the time resolve OSA,” he mentioned. So, whereas signs could enhance, the affected person may nonetheless be in danger.

“[T]he approach I state it to sufferers is that extreme is extreme no matter whether or not it is extremely extreme or on the decrease finish of the extreme class,” mentioned Patel.

In these circumstances, he steered that GLP-1s needs to be seen as a device to complement different therapies that deal with the anatomical points that trigger OSA, comparable to hypoglossal nerve stimulation with Encourage remedy.

Additional, those that are initially not good candidates for Encourage because of full concentric collapse generally turn out to be candidates upon weight reduction, Patel mentioned.

James J. Chao, MD, FACS, a board licensed surgeon and weight reduction specialist, and co-founder and chief medical officer at VedaNu Wellness, mentioned that individuals with sleep apnea ought to talk about utilizing a GLP-1 as part of their therapy plan. Chao wasn’t concerned within the examine.

Chao mentioned that individuals with OSA ought to hold utilizing their CPAP whereas they bear remedy. “When you’ve been handled for 12 months, you’ll must repeat the sleep examine to see when you’ve achieved a discount in apnea,” he advised Healthline.

Chao famous that therapy with a GLP-1 may be costly, operating round $1,000 per thirty days. “[M]edical insurance coverage protection relies on the codes your physician can submit for protection,” he mentioned.

Zepbound (tirzepatide) is at present the one weight loss medication that’s FDA permitted for the therapy of average to extreme OSA in adults with weight problems.